An interventional study of Nerve Conduction Study in Rheumatoid Arthritis, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by Sohag University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Arthritis, Rheumatoid by Sohag University — 10 open to participants now, 11 under way, 1 of them phase 3. Arthritis, Rheumatoid · Sohag University.
Among the 20 studies in Arthritis, Rheumatoid by Sohag University, this one is one of 3 that started in 2025, is one of 7 with no phase, reaches primary completion later than 3 of the 10 other live ones, and was the 13th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →10 of the 20 studies in Arthritis, Rheumatoid by Sohag University are open now, in 1 country. Recruiting first, the newest first:
Sohag University · Sites in Egypt
Ages 18+ · Healthy volunteers
Sohag University · Sites in Egypt
Ages 20–65
Sohag University
Ages 18+ · Healthy volunteers
Sohag University
Ages 18+
Sohag University
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 60 across the 8 interventional studies, 126 across the 12 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.
6 of the studies in Arthritis, Rheumatoid by Sohag University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07814989Sohag UniversityWrist Nerve Block as a New Treatment in Patients With Rheumatoid Arthritis | 2027-01-01 |
| NCT07801261Sohag UniversityEvaluation of Functional Disability in Rheumatoid Arthritis Patients | 2027-01-20 |
| NCT07878611Sohag UniversityMusclockeletal Ultra-sound Assessment of Pulley Inflammation in Rheumatoid Arthrits Pateints | 2027-03 |
| NCT07393217Sohag UniversityCorrelation Between Circulating Fibroblast Activation Protein (FAP) and Fibrosis in Two Diseases (Rheumatoid Arthritis and Systemic Sclerosis) | 2027-03-01 |
| NCT07381296Sohag UniversityPrognostic Factors and Predictors of Disease Flare in Patients With Rheumatoid Arthritis | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 20 studies in Arthritis, Rheumatoid by Sohag University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Rheumatoid arthritis is a chronic, systemic, autoimmune inflammatory disease that mainly affects the joints and periarticular soft tissues. Baricitinib (Olumiant®) is an oral, targeted synthetic DMARD that inhibits JAK1 and JAK2, which are implicated in the pathogenesis of rheumatoid arthritis (RA). Nerve conduction studies (NCSs) are an essential tool in the evaluation of the peripheral nervous system. The sensory nerve action potential (SNAP) provides information on the sensory nerve axon and its pathway from the distal receptors in the skin to the dorsal root ganglia, while the compound muscle action potential (CMAP) is an assessment of the motor nerve fibers from their origins in the anterior horn cell to their termination along muscle fibers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: Nerve Conduction Study
Device: Nerve Conduction Study
Sensory and Motor Nerve Conduction study on upper and lower limbs.
prevalence of Peripheral Neuropathy in Rheumatoid Arthritis Patients on Baricitinib
Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on Baricitinib in comparison to those on conventional synthetic DMARDs.
Time frame: 6 months
Plan to share: Undecided
Ran from May 2025 to primary completion in Nov 2025, 6 months.
Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 6 months is below that.
Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.